<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698802</url>
  </required_header>
  <id_info>
    <org_study_id>EX1000-1919</org_study_id>
    <nct_id>NCT00698802</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes</brief_title>
  <official_title>Assessment of Safety and Efficacy of Biphasic Human Insulin IU 100 to EX1000 on Glycaemic Control in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Asia and Africa. This trial aims for a comparison of blood glucose
      control of biphasic human insulin 100 IU/mL and EX1000.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>after 8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>For the duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fructosamine</measure>
    <time_frame>For the duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG</measure>
    <time_frame>For the duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-point SMPG profiles</measure>
    <time_frame>For the duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycaemic episodes</measure>
    <time_frame>For the duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events (including injection site reactions)</measure>
    <time_frame>For the duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory safety parameters (haematology, biochemistry and lipids)</measure>
    <time_frame>For the duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination and vital signs</measure>
    <time_frame>For the duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily insulin dosages</measure>
    <time_frame>For the duration of the trial</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">397</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EX1000</intervention_name>
    <description>Treat-to-target titration scheme, s.c. injection</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic human insulin</intervention_name>
    <description>Treat-to-target titration scheme, s.c. injection</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes for at least 12 months

          -  Current biphasic human insulin (BHI) for at least 3 months - as monotherapy or as the
             only insulin in combination with OADs

          -  Body Mass Index (BMI) less than or equal to 40.0 kg/m2

          -  HbA1c less than or equal to 9.5%

          -  FPG (SMPG) less than or equal to 12 mmol/L

        Exclusion Criteria:

          -  Treatment with more than 1IU/kg insulin daily

          -  Treatment with Glucagon-like peptide 1 mimetics or dipeptityl peptidase IV inhibitors

          -  Known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the
             Investigator

          -  Known or suspected allergy to trial products or related products

          -  Receipt of any investigational drug within one month prior to this trial

          -  Any other condition that the Investigator feels would interfere with trial
             participation or evaluation of results, e.g. shiftworkers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Vijayawada</city>
        <zip>520002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abu Dhabi</city>
        <zip>51900</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>South Africa</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

